The battle between surgical devices maker Intuitive Surgical (NSDQ:ISRG) and analysts at Citron Group continues to heat up, with harsh words from one and a stern defense from the other.
Citron puts Intuitive Surgical on blast over adverse events
Citron Research
Intuitive Surgical: What’s with all the adverse event reports?
Investors yawn at latest Citron jab, send Intuitive Surgical shares up
Investors, who sent shares of Intuitive Surgical (NSDQ:ISRG) down 10% the 1st time Citron Research issued a negative report on the medical device company, yawned today at a 3rd missive from the short seller.
ISRG shares were up slightly as of about 3:30 p.m. today to $561.07 apiece, despite Citron’s repeated assertion that the stock is headed for $300 per share.
Second negative report hits Intuitive Surgical, but shares rally on positive Goldman Sachs update
Shares of Intuitive Surgical (NSDQ:ISRG) came under pressure early yesterday on a negative report from hedge fund Citron Research, before rallying after Goldman Sachs boosted its price target on the stock.
Negative rating slashes 10% from Intuitive Surgical | Wall Street Beat
A research report blasting Intuitive Surgical (NSDQ:ISRG) spooked investors on Wall Street yesterday and today, prompting a selloff that’s shaved some 11% from the medical device company’s share price.
